Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global CAR-T r/r CLL Market Forecast to 2030 - Research and Markets

Research and Markets
Posted on: 05 Oct 17

The "CAR-T r/r CLL Global Market Forecast" report has been added to Research and Markets' offering.

Novel immune-therapeutic approaches in development for CLL includemonoclonal antibodies, bi-specific antibodies, anti-PD1/PDL-1 checkpoint inhibitors, and the CAR-T cell therapies including JCAR014/JCAR017 (Juno Therapeutics), KTE-C19 (Kite Pharma), and CTL019 (tisagenlecluecel-T)(Novartis Pharmaceuticals). These potential CAR-T therapies or their next generations e.g. armoured' CARs and humanized versions are in development.

This product consists of a detailed Executive presentation (~130 slides, .pdf) and MS-Excel workbook forecasting the commercial potential ($ 000s) of novel CAR-T therapies in r/r CLL across 9 major Western markets to 2030.

A patient based flow methodology has been devised where possible intervention scenarios for CAR-T introduction are visualised so that the optimum product positioning can be assessed. In addition, an up-to-date review of CLL disease background, epidemiology, current and future treatments is presented along with a comprehensive review of the CAR-T CLL competitive landscape. Pricing, cost effectiveness, manufacturing and logistical considerations are also discussed. All assumptions are clearly provided.

Key Topics Covered:

1. Executive Summary

2. Car-T Treatment For R/R Cll - Commercial Model: Key Outputs

3. Chronic Lymphocytic Leukaemia - Disease Background

4. Chronic Lymphocytic Leukaemia - Epidemiology

5. Chronic Lymphocytic Leukaemia - Treatment

6. Novel Treatments For Cll - Immunotherapy Approaches

7. Novel Treatments For Cll - Modelling Commercial Potential Of Car-T Cell Therapies

8. Bibliography

Companies Mentioned

  • Axi-Cel
  • Juno Therapeutics Inc.
  • Kite Pharma/Gilead
  • Novartis

For more information about this report visit

View source version on

Business Wire

Last updated on: 05/10/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.